Cyclacel Historical Balance Sheet

CYCC Stock

USD 0.40 0.01 2.56%

Trend analysis of Cyclacel Pharmaceuticals balance sheet accounts such as Total Stockholder Equity of 576.6 K, Other Assets of 0.95 or Common Stock Shares Outstanding of 893.4 K provides information on Cyclacel Pharmaceuticals' total assets, liabilities, and equity, which is the actual value of Cyclacel Pharmaceuticals to its prevalent stockholders. By breaking down trends over time using Cyclacel Pharmaceuticals balance sheet statements, investors will see what precisely the company owns and what it owes to creditors or other parties at the end of each accounting year.

Cash Flow Balance Sheet Income Statement

Housing Crash

Credit Downgrade

Yuan Drop

Covid

Financial Statement Analysis is much more than just reviewing and examining Cyclacel Pharmaceuticals latest accounting reports to predict its past. Macroaxis encourages investors to analyze financial statements over time for various trends across multiple indicators and accounts to determine whether Cyclacel Pharmaceuticals is a good buy for the upcoming year.

Cyclacel Pharmaceuticals Inventory

(4.82 Million)

Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in Cyclacel Pharmaceuticals. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in main economic indicators.

For information on how to trade Cyclacel Stock refer to our How to Trade Cyclacel Stock guide.

About Cyclacel Balance Sheet Analysis

Balance Sheet is a snapshot of the financial position of Cyclacel Pharmaceuticals at a specified time, usually calculated after every quarter, six months, or one year. Cyclacel Pharmaceuticals Balance Sheet has two main parts: assets and liabilities. Liabilities are the debts or obligations of Cyclacel Pharmaceuticals and are divided into current liabilities and long term liabilities. An asset, on the other hand, is anything of value that can be converted into cash and which Cyclacel currently owns. An asset can also be divided into two categories, current and non-current.

Cyclacel Pharmaceuticals Balance Sheet Chart

At present, Cyclacel Pharmaceuticals' Total Liabilities is projected to decrease significantly based on the last few years of reporting. The current year's Non Current Assets Total is expected to grow to about 1.7 M, whereas Total Assets are forecasted to decline to about 8.4 M.

Total Assets Common Stock Shares Outstanding Other Stockholder Equity Total Liab

Add Fundamental

Total Assets

Total assets refers to the total amount of Cyclacel Pharmaceuticals assets owned. Assets are items that have some economic value and are expended over time to create a benefit for the owner. These assets are usually recorded in Cyclacel Pharmaceuticals books under different categories such as cash, marketable securities, accounts receivable,prepaid expenses, inventory, fixed assets, intangible assets, other assets, marketable securities, accounts receivable, prepaid expenses and others. The total value of all owned resources that are expected to provide future economic benefits to the business, including cash, investments, accounts receivable, inventory, property, plant, equipment, and intangible assets.

Common Stock Shares Outstanding

The total number of shares of a company's common stock that are currently owned by all its shareholders.

Total Liab

The total amount of all liabilities that a company has, including both short-term and long-term liabilities.

Most accounts from Cyclacel Pharmaceuticals' balance sheet are interrelated and interconnected. However, analyzing balance sheet accounts one by one will only give a small insight into Cyclacel Pharmaceuticals current financial condition. On the other hand, looking into the entire matrix of balance sheet accounts, and analyzing their relationships over time can provide a more complete picture of the company financial strength now and in the future. Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in Cyclacel Pharmaceuticals. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in main economic indicators.

For information on how to trade Cyclacel Stock refer to our How to Trade Cyclacel Stock guide.At present, Cyclacel Pharmaceuticals' Total Liabilities is projected to decrease significantly based on the last few years of reporting. The current year's Non Current Assets Total is expected to grow to about 1.7 M, whereas Total Assets are forecasted to decline to about 8.4 M.

	2021	2022	2023	2024 (projected)
Total Liabilities	5.3M	12.0M	8.2M	14.1M
Other Stockholder Equity	423.0M	414.0M	429.8M	284.3M

Total Liab Other Stockholder Equity

Cyclacel Pharmaceuticals balance sheet Correlations

	Total Assets	Total Stockholder Equity	Retained Earnings	Other Assets	Common Stock Shares Outstanding	Other Stockholder Equity	Total Liab	Short Long Term Debt Total	Other Current Liab	Total Current Liabilities	Property Plant And Equipment Net	Current Deferred Revenue	Net Debt	Accounts Payable	Cash	Non Current Assets Total	Non Currrent Assets Other	Cash And Short Term Investments	Common Stock Total Equity	Short Term Investments	Non Current Liabilities Total	Other Current Assets	Property Plant And Equipment Gross	Total Current Assets	Short Term Debt	Common Stock
Total Assets		0.57	0.23	0.15	-0.34	0.01	0.02	0.14	-0.06	0.0	0.18	0.13	-0.69	-0.32	0.83	0.09	-0.02	0.94	0.09	0.09	0.12	-0.08	0.0	0.93	0.11	0.09
Total Stockholder Equity	0.57		-0.53	-0.72	-0.03	0.72	-0.8	-0.69	0.21	-0.69	-0.52	-0.73	-0.98	0.02	0.92	-0.58	-0.37	0.79	0.27	-0.3	-0.73	-0.03	-0.63	0.82	-0.73	0.02
Retained Earnings	0.23	-0.53		0.83	-0.67	-0.93	0.8	0.91	-0.19	0.72	0.69	0.86	0.37	-0.4	-0.19	0.37	0.04	0.05	0.13	0.61	0.84	-0.47	0.6	-0.04	0.86	-0.24
Other Assets	0.15	-0.72	0.83		-0.24	-0.85	0.97	0.97	-0.41	0.77	0.82	0.99	0.6	-0.36	-0.41	0.78	0.38	-0.15	-0.27	0.43	1.0	-0.06	0.8	-0.21	0.99	0.02
Common Stock Shares Outstanding	-0.34	-0.03	-0.67	-0.24		0.45	-0.16	-0.42	-0.03	-0.19	-0.42	-0.29	0.14	0.47	-0.25	0.16	0.51	-0.36	-0.44	-0.37	-0.27	0.76	-0.23	-0.28	-0.28	0.29
Other Stockholder Equity	0.01	0.72	-0.93	-0.85	0.45		-0.88	-0.9	0.21	-0.76	-0.68	-0.87	-0.59	0.35	0.44	-0.47	-0.17	0.21	-0.02	-0.58	-0.86	0.31	-0.68	0.3	-0.88	0.22
Total Liab	0.02	-0.8	0.8	0.97	-0.16	-0.88		0.93	-0.3	0.84	0.75	0.97	0.69	-0.26	-0.53	0.79	0.46	-0.28	-0.28	0.42	0.97	0.02	0.78	-0.33	0.97	0.04
Short Long Term Debt Total	0.14	-0.69	0.91	0.97	-0.42	-0.9	0.93		-0.45	0.72	0.85	0.99	0.57	-0.43	-0.38	0.62	0.16	-0.12	-0.16	0.47	0.98	-0.31	0.8	-0.2	0.99	-0.15
Other Current Liab	-0.06	0.21	-0.19	-0.41	-0.03	0.21	-0.3	-0.45		0.22	-0.57	-0.44	-0.24	0.57	0.14	-0.29	0.25	0.02	0.27	-0.04	-0.43	0.28	-0.56	0.09	-0.44	0.22
Total Current Liabilities	0.0	-0.69	0.72	0.77	-0.19	-0.76	0.84	0.72	0.22		0.41	0.75	0.56	0.17	-0.44	0.57	0.58	-0.26	-0.13	0.39	0.76	0.1	0.43	-0.27	0.76	0.09
Property Plant And Equipment Net	0.18	-0.52	0.69	0.82	-0.42	-0.68	0.75	0.85	-0.57	0.41		0.84	0.46	-0.69	-0.27	0.69	-0.09	-0.05	-0.21	0.32	0.84	-0.26	0.96	-0.13	0.83	-0.11
Current Deferred Revenue	0.13	-0.73	0.86	0.99	-0.29	-0.87	0.97	0.99	-0.44	0.75	0.84		0.61	-0.38	-0.42	0.73	0.29	-0.16	-0.24	0.45	1.0	-0.16	0.81	-0.23	1.0	-0.07
Net Debt	-0.69	-0.98	0.37	0.6	0.14	-0.59	0.69	0.57	-0.24	0.56	0.46	0.61		0.02	-0.97	0.54	0.32	-0.88	-0.31	0.18	0.62	0.07	0.6	-0.91	0.62	-0.01
Accounts Payable	-0.32	0.02	-0.4	-0.36	0.47	0.35	-0.26	-0.43	0.57	0.17	-0.69	-0.38	0.02		-0.15	-0.28	0.42	-0.27	-0.05	-0.28	-0.38	0.38	-0.61	-0.18	-0.37	0.17
Cash	0.83	0.92	-0.19	-0.41	-0.25	0.44	-0.53	-0.38	0.14	-0.44	-0.27	-0.42	-0.97	-0.15		-0.41	-0.3	0.96	0.28	-0.09	-0.43	-0.13	-0.44	0.97	-0.43	-0.01
Non Current Assets Total	0.09	-0.58	0.37	0.78	0.16	-0.47	0.79	0.62	-0.29	0.57	0.69	0.73	0.54	-0.28	-0.41		0.61	-0.23	-0.47	0.19	0.76	0.48	0.74	-0.23	0.72	0.43
Non Currrent Assets Other	-0.02	-0.37	0.04	0.38	0.51	-0.17	0.46	0.16	0.25	0.58	-0.09	0.29	0.32	0.42	-0.3	0.61		-0.24	-0.28	0.13	0.33	0.79	-0.01	-0.17	0.3	0.6
Cash And Short Term Investments	0.94	0.79	0.05	-0.15	-0.36	0.21	-0.28	-0.12	0.02	-0.26	-0.05	-0.16	-0.88	-0.27	0.96	-0.23	-0.24		0.23	0.04	-0.17	-0.19	-0.24	0.99	-0.17	-0.03
Common Stock Total Equity	0.09	0.27	0.13	-0.27	-0.44	-0.02	-0.28	-0.16	0.27	-0.13	-0.21	-0.24	-0.31	-0.05	0.28	-0.47	-0.28	0.23		0.58	-0.25	-0.32	-0.29	0.21	-0.24	-0.15
Short Term Investments	0.09	-0.3	0.61	0.43	-0.37	-0.58	0.42	0.47	-0.04	0.39	0.32	0.45	0.18	-0.28	-0.09	0.19	0.13	0.04	0.58		0.44	-0.12	0.29	-0.05	0.45	-0.1
Non Current Liabilities Total	0.12	-0.73	0.84	1.0	-0.27	-0.86	0.97	0.98	-0.43	0.76	0.84	1.0	0.62	-0.38	-0.43	0.76	0.33	-0.17	-0.25	0.44		-0.11	0.82	-0.24	1.0	-0.01
Other Current Assets	-0.08	-0.03	-0.47	-0.06	0.76	0.31	0.02	-0.31	0.28	0.1	-0.26	-0.16	0.07	0.38	-0.13	0.48	0.79	-0.19	-0.32	-0.12	-0.11		-0.12	-0.1	-0.15	0.61
Property Plant And Equipment Gross	0.0	-0.63	0.6	0.8	-0.23	-0.68	0.78	0.8	-0.56	0.43	0.96	0.81	0.6	-0.61	-0.44	0.74	-0.01	-0.24	-0.29	0.29	0.82	-0.12		-0.31	0.81	-0.14
Total Current Assets	0.93	0.82	-0.04	-0.21	-0.28	0.3	-0.33	-0.2	0.09	-0.27	-0.13	-0.23	-0.91	-0.18	0.97	-0.23	-0.17	0.99	0.21	-0.05	-0.24	-0.1	-0.31		-0.24	0.05
Short Term Debt	0.11	-0.73	0.86	0.99	-0.28	-0.88	0.97	0.99	-0.44	0.76	0.83	1.0	0.62	-0.37	-0.43	0.72	0.3	-0.17	-0.24	0.45	1.0	-0.15	0.81	-0.24		-0.08
Common Stock	0.09	0.02	-0.24	0.02	0.29	0.22	0.04	-0.15	0.22	0.09	-0.11	-0.07	-0.01	0.17	-0.01	0.43	0.6	-0.03	-0.15	-0.1	-0.01	0.61	-0.14	0.05	-0.08

Click cells to compare fundamentals

Cyclacel Pharmaceuticals Account Relationship Matchups

Cyclacel Pharmaceuticals balance sheet Accounts

	2019	2020	2021	2022	2023	2024 (projected)
Total Assets	15.3M	36.8M	42.6M	27.5M	8.8M	8.4M
Total Stockholder Equity	11.7M	33.3M	37.3M	15.5M	607K	576.7K
Retained Earnings	(357.6M)	(366.1M)	(385.0M)	(406.2M)	(428.3M)	(406.9M)
Common Stock Shares Outstanding	54.4K	242.2K	595.1K	657.6K	850.8K	893.4K
Liabilities And Stockholders Equity	15.3M	36.8M	42.6M	27.5M	8.8M	8.4M
Other Stockholder Equity	370.1M	400.1M	423.0M	414.0M	429.8M	284.3M
Total Liab	3.6M	3.5M	5.3M	12.0M	8.2M	14.1M
Other Current Liab	1.5M	2.0M	3.2M	4.8M	4.6M	3.4M
Total Current Liabilities	2.4M	2.5M	5.3M	7.4M	8.2M	5.8M
Property Plant And Equipment Net	1.3M	1.3M	94K	174K	102K	96.9K
Net Debt	(10.7M)	(32.3M)	(36.5M)	(18.2M)	(3.3M)	(3.5M)
Accounts Payable	890K	514K	2.1M	2.6M	3.5M	2.2M
Cash	11.9M	33.4M	36.6M	18.3M	3.4M	3.2M
Non Current Assets Total	1.3M	1.3M	1.6M	3.1M	1.4M	1.7M
Non Currrent Assets Other	(1.3M)	(1.3M)	1.6M	2.9M	1.3M	1.3M
Cash And Short Term Investments	11.9M	33.4M	36.6M	18.3M	3.4M	3.2M
Non Current Liabilities Total	1.2M	1.1M	30K	4.6M	37K	35.2K
Other Current Assets	103K	750K	4.4M	6.1M	4.1M	4.3M
Property Plant And Equipment Gross	1.3M	1.3M	94K	174K	522K	839.0K
Total Current Assets	14.0M	35.5M	40.9M	24.4M	7.4M	7.1M
Accumulated Other Comprehensive Income	(819K)	(746K)	(748K)	(1.3M)	(908K)	(953.4K)
Common Stock	17K	6K	10K	4.5M	1K	950.0
Net Receivables	1.3M	1.3M	3.7M	5.6M	2.9M	2.7M
Inventory	703K	684K	577K	(5.6M)	(5.1M)	(4.8M)
Property Plant Equipment	27K	106K	94K	174K	156.6K	148.8K
Retained Earnings Total Equity	(342.5M)	(349.8M)	(357.6M)	(366.1M)	(329.5M)	(345.9M)
Net Tangible Assets	11.7M	33.3M	37.3M	15.5M	17.8M	23.9M
Capital Surpluse	365.1M	365.8M	370.1M	400.1M	460.1M	394.6M
Non Current Liabilities Other	124K	100K	1.2M	1.1M	1.2M	1.3M
Net Invested Capital	11.7M	33.3M	37.3M	20.0M	607K	576.7K
Net Working Capital	11.6M	33.0M	35.6M	17.0M	(717K)	(681.2K)
Capital Stock	17K	6K	10K	4.5M	1K	950.0

Also Currently Popular

Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.

C	Citigroup
GM	General Motors
F	Ford Motor

When determining whether Cyclacel Pharmaceuticals offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of Cyclacel Pharmaceuticals' financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Cyclacel Pharmaceuticals Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Cyclacel Pharmaceuticals Stock:

How To Invest In Cyclacel

Details

Is Cyclacel Stock a good investment?

Details

What is Cyclacel Pharmaceuticals' Net Worth?

Details

Largest Biotechnology Companies

View

Largest Pharmaceuticals, Biotechnology & Life Sciences Companies

View

For information on how to trade Cyclacel Stock refer to our How to Trade Cyclacel Stock guide.

You can also try the Portfolio Volatility module to check portfolio volatility and analyze historical return density to properly model market risk.

Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Cyclacel Pharmaceuticals. If investors know Cyclacel will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Cyclacel Pharmaceuticals listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.

Earnings Share

(27.40)

Revenue Per Share

0.044

Quarterly Revenue Growth

(0.99)

Return On Assets

(1.03)

Return On Equity

(5.71)

The market value of Cyclacel Pharmaceuticals is measured differently than its book value, which is the value of Cyclacel that is recorded on the company's balance sheet. Investors also form their own opinion of Cyclacel Pharmaceuticals' value that differs from its market value or its book value, called intrinsic value, which is Cyclacel Pharmaceuticals' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Cyclacel Pharmaceuticals' market value can be influenced by many factors that don't directly affect Cyclacel Pharmaceuticals' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.

Please note, there is a significant difference between Cyclacel Pharmaceuticals' value and its price as these two are different measures arrived at by different means. Investors typically determine if Cyclacel Pharmaceuticals is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Cyclacel Pharmaceuticals' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.

Macroaxis helps investors of all levels and skills to maximize the upside of all their holdings and minimize the risk associated with market volatility, economic swings, and company-specific events. View terms and conditions

Feedback Blog

Made with optimal in San Francisco

2024 Macroaxis LLC

Cyclacel Historical Balance Sheet

Cyclacel Pharmaceuticals Inventory

(4.82 Million)

About Cyclacel Balance Sheet Analysis

Cyclacel Pharmaceuticals Balance Sheet Chart

Total Assets

Common Stock Shares Outstanding

Total Liab

Cyclacel Pharmaceuticals balance sheet Correlations

Cyclacel Pharmaceuticals Account Relationship Matchups

High Positive Relationship

High Negative Relationship

Cyclacel Pharmaceuticals balance sheet Accounts

Also Currently Popular

COMMON DESTINATIONS

MAIN CATEGORIES

COMPANY

Non Current Liabilities Total	+ 1.0	Other Assets
Non Current Liabilities Total	+ 1.0	Current Deferred Revenue
Short Term Debt	+ 1.0	Current Deferred Revenue
Short Term Debt	+ 1.0	Non Current Liabilities Total
Current Deferred Revenue	+ 0.99	Other Assets
Short Term Debt	+ 0.99	Other Assets

Net Debt	- 0.98	Total Stockholder Equity
Cash	- 0.97	Net Debt
Other Stockholder Equity	- 0.93	Retained Earnings
Total Current Assets	- 0.91	Net Debt
Short Long Term Debt Total	- 0.9	Other Stockholder Equity
Cash And Short Term Investments	- 0.88	Net Debt